PON1 haplotypes show genotype-dependent associations with dysglycemia and metabolic liver risk beyond paraoxonase activity

• by Laura Batista-Herrera, Maria João Meneses, Rogério T. Ribeiro, Luís Gardete-Correia, João F. Raposo, José Manuel Boavida, Carlos Penha-Gonçalves, Maria Paula Macedo

• July 7, 2026

Translating Continuous Glucose Monitoring Alarms Into Clinical Practice—Beyond Efficacy

• by Eileen R. Faulds

• August 20, 2026

Sympathetic ophthalmia complicating proliferative diabetic retinopathy: diagnostic and therapeutic challenges during pregnancy

• by Norah Alshabib, Motazz Alarfaj, Abdullah Albahlal, Nora A. Alyousif

• August 24, 2026

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

“There is incredible uncertainty in drug dosing.”

• by Arthur Allen

• August 20, 2026

• 15 min